{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:33:36Z","timestamp":1785818016841,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.leukres.2022.106821","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T23:59:09Z","timestamp":1646611149000},"page":"106821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Acute leukemia arising from myeloproliferative or myelodysplastic\/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry"],"prefix":"10.1016","volume":"115","author":[{"given":"Juan-Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Rodr\u00edguez-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Casal-Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Bergua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Algarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Luis","family":"L\u00f3pez-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Colorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Tormo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jos\u00e9","family":"Sayas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"L\u00f3pez-Pav\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Lavilla-Rubira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rodr\u00edguez-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Ignacio","family":"Rodr\u00edguez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Sanz-Caballer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2022.106821_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2022.106821_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ajh.23962","article-title":"Blast transformation in chronic myelomonocytic leukemia: risk factors, genetic features, survival, and treatment outcome","volume":"90","author":"Patnaik","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2022.106821_bib3","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2022.106821_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106821_bib5","article-title":"Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study","author":"Martinez-Cuadron","year":"2021","journal-title":"Blood Adv."},{"issue":"14","key":"10.1016\/j.leukres.2022.106821_bib6","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2022.106821_bib7","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2022.106821_bib8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2022.106821_bib9","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1080\/10428194.2018.1441408","article-title":"Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase","volume":"59","author":"Mollard","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2022.106821_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2018.05.004","article-title":"Outcomes and predictors of survival in blast phase myeloproliferative neoplasms","volume":"70","author":"Lancman","year":"2018","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.leukres.2022.106821_bib11","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41375-018-0143-8","article-title":"Blast phase chronic myelomonocytic leukemia: mayo-MDACC collaborative study of 171 cases","volume":"32","author":"Patnaik","year":"2018","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.leukres.2022.106821_bib12","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2022.106821_bib13","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.leukres.2022.106821_bib14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.leukres.2015.03.001","article-title":"Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN","volume":"39","author":"Andriani","year":"2015","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.leukres.2022.106821_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/bjh.15819","article-title":"Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia","volume":"185","author":"Kr\u00f6ger","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"19","key":"10.1016\/j.leukres.2022.106821_bib16","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1182\/bloodadvances.2020002621","article-title":"Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv."},{"issue":"16","key":"10.1016\/j.leukres.2022.106821_bib17","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/bloodadvances.2018019976","article-title":"Conditioning intensity in secondary AML with prior myelodysplastic syndrome\/myeloproliferative disorders: an EBMT ALWP study","volume":"2","author":"Sengsayadeth","year":"2018","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.leukres.2022.106821_bib18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bmt.2014.31","article-title":"Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"49","author":"Cahu","year":"2014","journal-title":"Bone Marrow Transpl."},{"issue":"2","key":"10.1016\/j.leukres.2022.106821_bib19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the myeloproliferative neoplasm subcommittee of the CMWP of the european group for blood and marrow transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"9","key":"10.1016\/j.leukres.2022.106821_bib20","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","article-title":"A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia","volume":"34","author":"Bose","year":"2020","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.leukres.2022.106821_bib21","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.leukres.2022.106821_bib22","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/bjh.17084","article-title":"Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients","volume":"191","author":"Gangat","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.leukres.2022.106821_bib23","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","article-title":"Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs","volume":"5","author":"Masarova","year":"2021","journal-title":"Blood Adv."},{"issue":"24","key":"10.1016\/j.leukres.2022.106821_bib24","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.leukres.2022.106821_bib25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2022.106821_bib26","doi-asserted-by":"crossref","first-page":"E433","DOI":"10.1002\/ajh.26334","article-title":"Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia","volume":"96","author":"Saliba","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2022.106821_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.33403","article-title":"A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia","author":"Vives","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2022.106821_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2022.106821_bib29","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2022.106821_bib30","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.leukres.2022.106821_bib31","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41375-020-01058-4","article-title":"Evolving treatment patterns and outcomes in older patients (>\/=60 years) with AML: changing everything to change nothing?","volume":"35","author":"Mart\u00ednez-Cuadr\u00f3n","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2022.106821_bib32","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","article-title":"Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes","volume":"5","author":"Hunter","year":"2021","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.leukres.2022.106821_bib33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"26","key":"10.1016\/j.leukres.2022.106821_bib34","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients With newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2022.106821_bib35","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.leukres.2022.106821_bib36","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2022.106821_bib37","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:25Z","timestamp":1758934945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622000479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":37,"alternative-id":["S0145212622000479"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106821","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute leukemia arising from myeloproliferative or myelodysplastic\/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106821"}}